Bayer Spain has presented the fifth edition of its Impact Report, with an investment of 145 million euros in 2025. The company has reduced its CO2 emissions by 40% since 2019.
According to notimerica.com, Bayer Spain has presented the fifth edition of its Impact Report, a document that outlines its progress in health, agriculture, social collaboration, and emission reductions. The company reports a 40% decrease in its CO2 emissions across scopes 1, 2, and 3 since 2019.
In health innovation, Spain participates in 60% of Bayer's major global projects. The country has over 40 clinical trials in phases I-IV and observational studies, collaborating with more than 500 public and private centres.
The investment in Spain was 145 million euros in 2025, of which 120 million was allocated to innovation and 25 million to infrastructure. Since 2019, the accumulated amount totals 712 million.
“Our commitment to Spain, after 127 years of presence and growth in the country, goes beyond our activity”
This was expressed by Bayer's CEO for Spain and Portugal, Jordi Sánchez, during the report presentation.
In agriculture, the company allocated 25.8 million euros to R&D in 2025. Its centres in Sevilla, Almería, and Murcia are working on new molecules, high-yield seeds, and horticulture.
The La Felguera plant (Asturias) will be the first pharmaceutical active ingredient plant in Spain to eliminate direct emissions associated with steam. It will start operating at the end of this year and will prevent over 6,000 tonnes of CO2 per year.
At the Alcalá de Henares plant (Madrid), electricity has been 100% renewable since 2020, and 92% of waste is recycled. Since 2023, over 140 tonnes of contrast have been sent for iodine recovery.
The workforce in Spain exceeds 2,700 people from more than 50 nationalities, and 56% of management positions are held by women.
In 2025, the company received an AA rating from MSCI ESG Ratings. The World Benchmarking Alliance ranked it first in its Food & Agriculture Benchmark.
You may also like
